{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-010621","form_type":"8-K","ticker":"LYRA","cik":"0001327273","company_name":"Lyra Therapeutics, Inc.","filed_at":"2023-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.436497+00:00","generated_at":"2026-06-17T10:10:19.081715+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Lyra Therapeutics reports FY2022 net loss $55.3M; cash $97.9M; ENLIGHTEN I on track for mid-2023 enrollment completion","bullets":["Net loss for FY2022 $55.3M vs $43.5M in 2021; Q4 net loss $14.2M.","Cash and investments $97.9M as of Dec 31, 2022; sufficient into mid-2024.","ENLIGHTEN I Phase 3 enrollment completion on track for mid-2023; ENLIGHTEN II resume enrollment Q2 2023 (ahead of prior Q3 2023).","BEACON Phase 2 data for LYR-220 expected Q4 2023.","Transitioned manufacturing in-house to prepare for commercial production."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-010621","json":"https://secwatch.observer/filing/0000950170-23-010621.json","markdown":"https://secwatch.observer/filing/0000950170-23-010621.md","text":"https://secwatch.observer/filing/0000950170-23-010621.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1327273/000095017023010621/0000950170-23-010621-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1327273/000095017023010621/lyra-20230329.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T10:10:19.081715+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0d6881c6fb56e37981d3055bdce84bd1e97b6456","claim":"Lyra Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2022 results: net income Net loss for the fourth quarter and full year ended December 31, 2022 was $14.2 million and $55.3 million, respectively.","evidence_excerpt":"Lyra Therapeutics, Inc. (the “Company”) announced its financial results for the year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1327273/000095017023010621/0000950170-23-010621-index.htm","confidence":0.4,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2022"},{"label":"Net income","value":"Net loss for the fourth quarter and full year ended December 31, 2022 was $14.2 million and $55.3 million, respectively"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}